Realtime | Geld | Brief | Zeit |
---|---|---|---|
2,070 | 2,180 | 10.09. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.08. | Careium AB: President & CEO Christian Walén steps down from his position and Peter Heuman appointed as interim CEO | 245 | GlobeNewswire (Europe) | Careium's Board of Directors and Careium's President and CEO Christian Walén have mutually agreed that Christian Walén steps down from the role of President and CEO, effective immediately.
"The Board... ► Artikel lesen | |
11.07. | Careium AB: Careium reports second quarter results 2025 | 131 | GlobeNewswire (Europe) | The second quarter in summary
Net sales decreased 11.9 percent to SEK 202.1 million (229.4)Reported net sales was negatively impacted with SEK 15.1 million by the accounting of financial leases in Sweden... ► Artikel lesen | |
13.06. | Careium AB: Bulletin from the extraordinary general meeting on 13 June 2025 of Careium AB (publ) | 119 | GlobeNewswire (Europe) | The extraordinary general meeting ("EGM") of Careium AB (publ), 559121-5875, (the "Company") took place today, 13 June 2025.
The EGM resolved on all proposed matters in accordance with previously published... ► Artikel lesen | |
CAREIUM Aktie jetzt für 0€ handeln | |||||
24.04. | Careium AB: Careium reports first quarter results 2025 | 67 | GlobeNewswire (Europe) | The First Quarter in Summary
Net sales decreased 1.6 percent to SEK 207.4 million (210.7)Service sales increased 3.4 percent to SEK 160.3 million (155.0)Product sales decreased 15.5 percent to SEK 47.1... ► Artikel lesen | |
13.02. | Careium AB: Careium reports fourth quarter results 2024 | 467 | GlobeNewswire (Europe) | The Fourth Quarter in SummaryNet sales increased 14.8 percent to SEK 228.9 million (199.4)Service sales was SEK 165.9 million (154.1)Product sales was SEK 63.0 million (45.3)Gross margin increased to... ► Artikel lesen | |
25.10.24 | Careium AB: Careium reports third quarter results 2024 | 180 | GlobeNewswire (Europe) | The quarter in summary
Net sales amounted to SEK 201.7 million (217.3), a decrease of 7.2 percent, as sales cycles were affected by prolonged lifetime of analog (UK) and 2G/3G (SWE) networks
Service... ► Artikel lesen | |
13.09.24 | Careium AB: Careium revises full-year outlook due to infrastructure transition delays in the UK and Sweden | 201 | GlobeNewswire (Europe) | Careium, the European champion in technology enabled care, has revised its full-year growth outlook downward due to infrastructure transition delays affecting its business more than expected, and it... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 47,260 | +0,02 % | Fresenius platziert Anleihen im Volumen von 1 Milliarde Euro | DJ Fresenius platziert Anleihen im Volumen von 1 Milliarde Euro
DOW JONES--Fresenius hat nach fast zweijähriger Abwesenheit vom Euro-Anleihemarkt zwei Anleihen im Gesamtvolumen von 1 Milliarde... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 48,280 | +2,20 % | Siemens Healthineers: Die Langeweile setzt sich fort! | ||
THERMO FISHER | 407,55 | +0,07 % | Here's What Dragged Thermo Fisher Scientific (TMO) in Q2 | ||
EUROFINS SCIENTIFIC | 62,70 | +0,03 % | Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 August 2025 | Regulatory News:
Eurofins Scientific SE (Paris:ERF):
ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal... ► Artikel lesen | |
SYNLAB | 12,710 | 0,00 % | Schock-News für Synlab Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
DAVITA | 114,65 | +1,42 % | Working Together: DaVita Celebrates Joint Efforts To Advance Kidney Health Awareness and Access to Care | NORTHAMPTON, MA / ACCESS Newswire / September 9, 2025 / Kidney disease affects an estimated 35 million Americans, with 90% unaware until it's critical. As DaVita celebrates its 25th anniversary, it... ► Artikel lesen | |
DENTSPLY SIRONA | 11,825 | +1,03 % | DENTSPLY SIRONA Inc.: Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business Following Comprehensive Review of Strategic Alternatives | CHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced that the Company has completed the evaluation of strategic... ► Artikel lesen | |
SMITH & NEPHEW | 16,255 | -0,79 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 05.09.2025 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
SONIC HEALTHCARE | 12,936 | +0,81 % | SONIC HEALTHCARE LIMITED: Change of Director's Interest Notice | ||
DIASORIN | 81,36 | -0,25 % | Milan: DiaSorin falls | ||
PATTERSON COMPANIES | 27,400 | 0,00 % | Patterson Companies Completes Acquisition by Patient Square Capital | Robert Rajalingam Appointed Chief Executive Officer and to Board of Directors
ST. PAUL, Minn.--(BUSINESS WIRE)--Patterson Companies ("Patterson" or the "Company"), a leading supplier of products... ► Artikel lesen | |
FULGENT GENETICS | 18,800 | +0,53 % | Fulgent Genetics: UBS stuft Aktie auf 'Kaufen' hoch und verweist auf Wachstumspotenzial | ||
PERSPECTIVE THERAPEUTICS | 2,880 | +4,35 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results | [212Pb]VMT-a-NET study update presented at the 2025 ASCO Annual Meeting, based on updated interim results from a Phase 1/2a study in neuroendocrine tumors. As of the April 30, 2025 data cut-off date:... ► Artikel lesen | |
IMPLANTICA | 5,820 | +0,17 % | Implantica ramps-up production with 10,000 RefluxStop units in preparation for U.S. launch, pending FDA PMA approval | VADUZ, Liechtenstein, Sept. 10, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop®... ► Artikel lesen | |
OMNICELL | 27,400 | 0,00 % | Evoke Pharma, Inc.: Evoke Pharma and EVERSANA Expand GIMOTI Access to Gastro Health and Other Large GI Practices through Omnicell Relationship |